Abstract
Insulin is a potent inducer of mRNA transcription and translation, contributing to metabolic regulation. Insulin has also been suggested to regulate mRNA stability through the processing body (P-body) molecular machinery. However, whether and how insulin regulates mRNA stability via P-bodies is not clear. Here we show that the E3-ligase TRIM24 is a critical factor linking insulin signalling to P-bodies. Upon insulin stimulation, protein kinase B (PKB, also known as Akt) phosphorylates TRIM24 and stimulates its shuttling from the nucleus into the cytoplasm. TRIM24 interacts with several critical components of P-bodies in the cytoplasm, promoting their polyubiquitylation, which consequently stabilises Pparγ mRNA. Inactivation of TRIM24 E3-ligase activity or prevention of its phosphorylation via knockin mutations in mice promotes hepatic Pparγ degradation via P-bodies. Consequently, both knockin mutations alleviate hepatosteatosis in mice fed on a high-fat diet. Our results demonstrate the critical role of TRIM24 in linking insulin signalling to P-bodies and have therapeutic implications for the treatment of hepatosteatosis.
Introduction
Insulin is the primary conductor of metabolic homeostasis, traditionally recognized for its role in stimulating gene transcription and protein translation. However, the regulation of mRNA stability—a third critical pillar of gene expression—remains less understood in the context of insulin signaling. Processing bodies (P-bodies) are cytoplasmic, membrane-less organelles that serve as hubs for mRNA storage and degradation. While insulin was suspected to influence P-body dynamics, the molecular bridge connecting the insulin receptor to this machinery was previously unidentified. This study identifies the E3-ligase TRIM24 as this missing link, demonstrating how its insulin-dependent regulation controls hepatic lipid metabolism.
Identification of TRIM24 as an Akt Substrate
To identify novel insulin-responsive proteins, researchers performed phospho-proteomic analysis on mouse livers. Using a generic phospho-Akt substrate (PAS) antibody, they isolated proteins phosphorylated in response to insulin stimulation. TRIM24 emerged as a top candidate, showing significant insulin-induced phosphorylation and high intensity in mass spectrometry assays.
Biochemical validation confirmed that Akt (PKB) directly phosphorylates TRIM24 at Ser1043. This phosphorylation event acts as a molecular switch, triggering the translocation of TRIM24 from its typical residence in the nucleus to the cytoplasm.
Mechanism: From Nuclear Shuttling to mRNA Stabilization
Once in the cytoplasm, TRIM24 associates with P-bodies, specifically interacting with the scaffold protein EDC4 and the RNA-induced silencing complex component AGO2. The authors propose the existence of specialized "TRIM24-associated P-bodies" (TAP-bodies), suggesting that P-body populations are heterogeneous and can be specialized for specific signaling pathways.
TRIM24 functions as an E3 ligase in this context, polyubiquitylating EDC4 and AGO2. Rather than targeting these proteins for proteasomal degradation, this modification appears to inhibit their ability to facilitate mRNA decay. The primary metabolic consequence of this inhibition is the stabilization of Pparγ mRNA, a master regulator of adipogenesis and lipid synthesis. By preventing the degradation of Pparγ transcripts, insulin-activated TRIM24 promotes lipid accumulation in the liver.
Therapeutic Potential in Hepatosteatosis
The physiological relevance of this pathway was demonstrated using CRISPR/Cas9-engineered mouse models. Mice carrying either a non-phosphorylatable TRIM24 mutation (S1043A) or an E3-ligase-inactive mutation (C52/55A) were significantly protected from diet-induced hepatosteatosis. On a high-fat diet, these mutant mice exhibited a marked reduction in hepatic triglycerides compared to wild-type controls. This protection stems from the loss of Pparγ mRNA stabilization; without functional TRIM24 signaling, Pparγ transcripts are rapidly degraded within P-bodies, preventing excessive fat buildup.
Conclusion and Future Directions
This study establishes TRIM24 as a critical regulator linking insulin signaling to cytoplasmic mRNA stability. While the findings offer a promising therapeutic avenue for treating fatty liver disease, the dual role of TRIM24 as an oncoprotein in various cancers necessitates careful consideration in drug development. Future research is required to fully elucidate the structural mechanism by which ubiquitylation inhibits P-body enzymes and to identify other metabolic transcripts regulated through TAP-bodies.
Summary updated